Recent news on Iloprost

Actelion announces first quarter results 2007  -  Apr 19, 2007
PharmaLive.com (press release),Thereby, Actelion strengthened its PAH franchise by adding Ventavis® (iloprost) to its product offerings in the United Sates. Ventavis® is the only approved

Actelion Announces First Quarter Results 2007  -  Apr 18, 2007
Primenewswire (press release),Thereby, Actelion strengthened its PAH franchise by adding Ventavis(r) (iloprost) to its product offerings in the United Sates.

New Strategies for Pulmonary Arterial Hypertension: Evaluation and ...  -  Apr 23, 2007
Medscape (subscription)Drugs attempting to correct the prostacyclin deficiency underlying PAH are the prostanoids (epoprostenol, treprostinil, and iloprost).

Gilead's Atripla, Lower Costs Provide Lift To First Quarter  -  Apr 22, 2007
BioWorld Online,That deal gave Actelion a second marketed PAH product in Ventavis (iloprost), an inhaled, synthetic prostacyclin analogue that gained FDA approval in 2004.

Lung Cancer Study Aims to Identify Early Detection and Prevention ...  -  Mar 31, 2007
eMaxHealth.com,Keith and his colleagues will be testing the drug Iloprost® through the UCCC at both the University of Colorado Hospital and Denver VA Medical Center.

Actelion Announces Full Year 2006 Financial Results  -  Feb 21, 2007
Primenewswire (press release),Actelion is also continuing the VISION program previously initiated by CoTherix, evaluating the safety and efficacy of Ventavis(r) (inhaled iloprost) on top

Results of Inhaled Treprostinil Controlled Pilot Studies Reported ...  -  Feb 13, 2007
Drug Newswire (press release),The studies demonstrated, with a p-value < 0.0001, that VIVETA was more effective than a comparator molecule (iloprost) in producing a sustained reduction

Specialty Infusion Brings New Challenges, Solutions to Payers  -  Feb 12, 2007
Atlantic Information Services, Inc.,Mather also suggested that plans take a second look at certain self-administered drugs, such as Ventavis (iloprost) for pulmonary arterial hypertension.

Preventing Lung Cancer  -  Jan 2, 2007
WFtv.com,ILOPROST: Patients take three pills, two times a day of a drug called Iloprost -- marketed as Ventavis. It's a synthetic compound that basically mimics the

Switzerland's Actelion seals acquisition of CoTherix  -  Jan 9, 2007
Pharma Times (subscription),...will now be getting hold of CoTherix' Ventavis (iloprost) Inhalation Solution, the only approved inhaled therapy for the treatment of PAH in the USA.

Doctors Hope Drug Can Prevent Lung Cancer  -  Jan 2, 2007
WFtv.com,The drug iloprost works by boosting levels of a compound called PGI2. Lung cancer patients have low levels of PGI2. It shrank tumors in mice by more than 70

Preventing Lung Cancer  -  Jan 3, 2007
ABC30.com,Iloprost is already FDA approved for pulmonary hypertension in children, so Dr. Massion says if it holds out in studies, it could be available to patients

Pulmonary Hypertension Patients Improve From Combination Therapy  -  Dec 6, 2006
Medical News Today (press release),For patients with pulmonary arterial hypertension (PAH), adding inhaled iloprost to treatment with bosentan - two different classes of drugs often used

Pulmonary Hypertension Patients Improve From Combination Therapy  -  Dec 1, 2006
DG NewsThe researchers gave 32 patients both bosentan and inhaled iloprost, a prostacyclin analog. The remaining patients received bosentan and a placebo.

Combination Therapy Eases Pulmonary Arterial Hypertension  -  Dec 1, 2006
Forbes,1 (HealthDay News) -- A combination therapy of two drugs -- inhaled iloprost and bosentan -- appears to improve the condition of patients with pulmonary

Combination therapy effective for hypertension, say researchers  -  Dec 1, 2006
Pharmaceutical Business ReviewThe results shows that adding inhaled iloprost to treatment with bosentan increases exercise capability, reduces clinical deterioration and, in some cases,

Preventing Lung Cancer  -  Dec 5, 2006
WTVF,Iloprost is already approved by the US Food and Drug Administration for pulmonary hypertension in children, so Massion said if it holds out in studies,

New Pulmonary Hypertension Therapy Created  -  Dec 7, 2006
Playfuls.com,The University of Michigan scientists found adding inhaled iloprost to treatment with bosentan -- two different classes of drugs often used individually to

Biotech Has Lackluster Month of November  -  Dec 3, 2006
Drug Newswire (press release),Swiss-based Actelion Ltd plans to acquire CoTherix, Inc., which markets Ventavis (iloprost), the only approved inhaled therapy for the treatment of

Combo Therapy Superior for Pulmonary Arterial Hypertension  -  Dec 1, 2006
MedPage Today,1 -- Combining Ventavis (iloprost) with Tracleer (bosentan) may improve clinical and functional outcomes in pulmonary arterial hypertension, according to a

Inhaled Iloprost Well-Tolerated In Children With Pulmonary ...  Oct 31, 2006
Inhaled iloprost administered to children with pulmonary arterial hypertension (PAH) was shown to be safe and effective in a new study from the University of ... -Medical News Today (press release), Inhaled Iloprost May Increase Airway Obstruction In Children  Oct 31, 2006
A new study shows that inhaled iloprost, recently introduced to treat pulmonary arterial hypertension (PAH), can lead to acute lower airway obstruction in ... -Medical News Today (press release), CoTherix Reports Third Quarter Results  Nov 2, 2006
Net product sales for Ventavis(R) (iloprost) Inhalation Solution in the third quarter of 2006 were $18.4 million, an increase of 13 percent over the second ... -Drug Newswire (press release), Pulmonary Hypertension Treatment in Children and Thyroid ...  Oct 30, 2006
A new study shows that inhaled iloprost, recently introduce to treat pulmonary arterial hypertension (PAH), can lead to acute lower airway obstruction in ... -Medical News Today (press release), Zacks Bull and Bear of the Day Highlights: CoTherix, Sony, Grey ...  Nov 3, 2006
The company’s first product, Ventavis (iloprost) Inhalation Solution, launched in March 2005 for the treatment of pulmonary arterial hypertension (PAH). ... -Business Wire (press release), CoTherix Reports Third Quarter Results  Nov 1, 2006
We are also in the final stages of selecting a dry powder formulation of iloprost and look forward to commencing our Phase I program in the first half of 2007 ... -Earthtimes.org CoTherix to Webcast Presentations at Two Upcoming Investor ...  Oct 27, 2006
CoTherix currently markets Ventavis(r) (iloprost) Inhalation Solution in the United States for the treatment of PAH (WHO Group I). The Company is also ... -Yahoo! News (press release) Exercise and Respiratory Training Ease Life With Pulmonary ...  Sep 19, 2006
Baseline drug therapy included Tracleer (bosentan), Revatio (sildenafil), Ventavis (iloprost), Flolan (epoprostenol), beraprost, and calcium channel blockers. ... -MedPage Today

CoTherix to Webcast Presentations at Two Upcoming Investor ...  Aug 29, 2006
CoTherix currently markets Ventavis® (iloprost) Inhalation Solution in the United States for the treatment of PAH (WHO Group I). The Company is also ... -Yahoo! News

Preventing Lung Cancer  -  Dec 6, 2006
ABC7Chicago.com,ILOPROST: Patients take three pills, two times a day of a drug called Iloprost -- marketed as Ventavis. It's a synthetic compound that basically mimics the

Pulmonary Hypertension Patients Improve From Combination Therapy  -  Dec 6, 2006
Medical News Today (press release),For patients with pulmonary arterial hypertension (PAH), adding inhaled iloprost to treatment with bosentan - two different classes of drugs often used

Pulmonary Hypertension Patients Improve From Combination Therapy  -  Dec 1, 2006
DG NewsThe researchers gave 32 patients both bosentan and inhaled iloprost, a prostacyclin analog. The remaining patients received bosentan and a placebo.

Combination Therapy Eases Pulmonary Arterial Hypertension  -  Dec 1, 2006
Forbes,1 (HealthDay News) -- A combination therapy of two drugs -- inhaled iloprost and bosentan -- appears to improve the condition of patients with pulmonary

Preventing Lung Cancer  -  Dec 5, 2006
WTVF,Iloprost is already approved by the US Food and Drug Administration for pulmonary hypertension in children, so Massion said if it holds out in studies,

New Pulmonary Hypertension Therapy Created  -  Dec 7, 2006
Playfuls.com,The University of Michigan scientists found adding inhaled iloprost to treatment with bosentan -- two different classes of drugs often used individually to

Combination therapy effective for hypertension, say researchers  -  Dec 1, 2006
Pharmaceutical Business ReviewThe results shows that adding inhaled iloprost to treatment with bosentan increases exercise capability, reduces clinical deterioration and, in some cases,

Actelion buys US biopharma co Cotherix for 420 mln usd  -  Nov 19, 2006
Forbes,Cotherix, which is headquartered in Brisbane, California, is maker of Ventavis (iloprost), the only approved inhaled therapy for the treatment of Pulmonary

Actelion Purchases CoTherix for $420M  -  Nov 20, 2006
Genetic Engineering News (press release),CoTherix currently markets Ventavis® (iloprost), an approved inhaled therapy for the treatment of pulmonary arterial hypertension in the US

Actelion Announces Definitive Agreement to Acquire US-Based ...  -  Nov 19, 2006
PR Newswire (press release),CoTherix currently markets Ventavis(R) (iloprost), the only approved inhaled therapy for the treatment of Pulmonary Arterial Hypertension in the United

Actelion Announces Definitive Agreement to Acquire US-Based ...  -  Nov 19, 2006
Earthtimes.orgVentavis(R) (iloprost) Inhalation Solution was approved by the US Food and Drug Administration for the treatment of PAH (WHO Group I) in patients with NYHA

Biotech Has Lackluster Month of November  -  Dec 3, 2006
Drug Newswire (press release),Swiss-based Actelion Ltd plans to acquire CoTherix, Inc., which markets Ventavis (iloprost), the only approved inhaled therapy for the treatment of

Combo Therapy Superior for Pulmonary Arterial Hypertension  -  Dec 1, 2006
MedPage Today,1 -- Combining Ventavis (iloprost) with Tracleer (bosentan) may improve clinical and functional outcomes in pulmonary arterial hypertension, according to a

Actelion Adding PAH Power With $420M CoTherix Buyout  -  Nov 21, 2006
BioWorld Online,It would give Actelion a second marketed product in PAH - Ventavis (iloprost), an inhaled, synthetic prostacyclin analogue that gained FDA approval Dec.

Actelion announces definitive agreement to acquire US-based ...  -  Nov 21, 2006
PipelineReview.com (press release),CoTherix currently markets Ventavis® (iloprost), the only approved inhaled therapy for the treatment of Pulmonary Arterial Hypertension in the United States

Actelion Announces Definitive Agreement to Acquire US-Based ...  -  Nov 19, 2006
PrimeZone (press release),CoTherix currently markets Ventavis(r) (iloprost), the only approved inhaled therapy for the treatment of Pulmonary Arterial Hypertension in the United

CoTherix Reports Second Quarter Results  Aug 2, 2006
Net product sales for Ventavis® (iloprost) Inhalation Solution in the second quarter of 2006 were $16.2 million, up 12 percent from the previous quarter. ... -Yahoo! News

Crystal Research Associates, LLC Issues Executive Informational ...  Jul 31, 2006
CoTherix currently markets Ventavis® (iloprost) Inhalation Solution, approved by the US Food and Drug Administration (FDA) in December 2004 and launched in ... -Market Wire

CoTherix to Webcast Presentation at the CE Unterberg Emerging ...  Jul 7, 2006
CoTherix currently markets Ventavis(R) (iloprost) Inhalation Solution for the treatment of pulmonary arterial hypertension (PAH) in the United States in ... -Boursorama

CoTherix to Host Conference Call on August 2, 2006 to Announce ...  Jul 17, 2006
CoTherix currently markets Ventavis® (iloprost) Inhalation Solution in the United States for the treatment of PAH (WHO Group I). CoTherix and the CoTherix ... -Yahoo! News

Zacks Bull and Bear of the Day Highlights: CoTherix, Solectron ...  Jul 3, 2006
The company's first product, Ventavis (iloprost) Inhalation Solution, launched in March 2005 for the treatment of pulmonary arterial hypertension (PAH). ... -Business Wire



CoTherix to Webcast Presentation at the Rodman & Renshaw Global ...  May 5, 2006
CoTherix markets Ventavis® (iloprost) Inhalation Solution in the United States for the treatment of pulmonary arterial hypertension (PAH) in patients with ... - Yahoo! News

CoTherix to Host Conference Call on May 3, 2006, to Announce First ...  Apr 21, 2006
CoTherix's Ventavis® (iloprost) Inhalation Solution was approved by the FDA in December 2004 for the treatment of pulmonary arterial hypertension (PAH) in ... - Yahoo! News





CoTherix Appoints Abhay Joshi as EVP and Chief Technical Officer  11 Apr 2006
CoTherix's Ventavis® (iloprost) Inhalation Solution was approved by the FDA in December 2004 for the treatment of pulmonary arterial hypertension (PAH) in ... - Yahoo! News

PAH: market ripe for expansion as big pharma interest increases  Mar 27, 2006
...by the launch of three new therapies and formulations in the US - United Therapeutics' IV Remodulin (treprostinil), CoTherix' Ventavis (iloprost), and Pfizer's ... - Pharmaceutical Business Review

CoTherix launches trial of Ventavis in combination with sildenafil ...  Mar 30, 2006
CoTherix, Inc., (CTRX) announced the initiation of a phase III trial of Ventavis (iloprost) Inhalation Solution in combination with sildenafil citrate. ... - Therapeutics Daily (subscription)

Encysive Shares Tumble On FDA Thelin Approvable Letter  Mar 27, 2006
...for the condition include the prostacyclins Remodulin (treprostinil sodium, from United Therapeutics Corp.) and the inhaled Ventavis (iloprost, from CoTherix ... - BioWorld Online (subscription)

CoTherix Initiates Trial of Ventavis in Combination With ...  Mar 8, 2006
...(Nasdaq: CTRX) today announced the initiation of a Phase III trial of Ventavis(R) (iloprost) Inhalation Solution in combination with sildenafil citrate. ... - PR Newswire



CoTherix to Webcast Presentation From Merrill Lynch Conference  Jan 30, 2006
CoTherix's Ventavis® (iloprost) Inhalation Solution was approved by the FDA in December 2004 for the treatment of pulmonary arterial hypertension (PAH) in ... - Yahoo! News

CoTherix Announces Fourth Quarter Ventavis Sales and 2006 Revenue ...  Jan 19, 2006
...(Nasdaq: CTRX - News) today announced that preliminary net product sales of Ventavis®(iloprost) Inhalation Solution in the fourth quarter of 2005 totaled ... - Yahoo! News

CoTherix Announces Fourth Quarter Ventavis Sales and 2006 Revenue ...  Jan 19, 2006
19 /PRNewswire-FirstCall/ -- CoTherix, Inc. (NASDAQ:CTRX) today announced that preliminary net product sales of Ventavis(R)(iloprost) Inhalation Solution in ... - Biotech Intelligence

CoTherix Announces Fourth Quarter Ventavis Sales and 2006 Revenue ...  Jan 19, 2006
...today announced that preliminary net product sales of Ventavis(R)(iloprost) Inhalation Solution in the fourth quarter of 2005 totaled approximately $11.0 ... - PharmaLive.com

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional